secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096173
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports Q2 net loss $14.4M; terminates epetraborole Phase 2/3 trial in TR-MAC lung disease
--------------------------------------------------------------------------------

- Cash, equivalents, and investments $104.5M at June 30, 2024; runway through 2027.
- Net loss $14.4M in Q2 2024 vs $15.8M in Q2 2023; R&D $12.1M, G&A $3.7M.
- Terminated Phase 2/3 EBO-301 trial after sputum culture conversion at Month 6 similar between arms; PRO tool validated.
- Plans to advance AN2-502998 into Phase 1 for Chagas disease in 2025 and epetraborole into Phase 2 for melioidosis.
- Published study on epetraborole efficacy against M. abscessus mouse lung infection model in Antimicrobial Agents and Chemotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017024096173/0000950170-24-096173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017024096173/antx-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer